<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02920528</url>
  </required_header>
  <id_info>
    <org_study_id>30612-01</org_study_id>
    <nct_id>NCT02920528</nct_id>
  </id_info>
  <brief_title>Subdissociative Dose Ketamine for Treatment of Acute Pain in Subjects With Chronic Pain</brief_title>
  <official_title>Subdissociative Dose Ketamine for Treatment of Acute Pain in Subjects With Chronic Pain: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Air Force Research Laboratory</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized controlled trial which will be conducted to determine&#xD;
      whether sub-dissociative dose ketamine (SDDK) can improve pain control in subjects with&#xD;
      chronic pain syndrome presenting to the emergency department with exacerbation of their&#xD;
      chronic pain. The investigators also aim to determine whether use of SDDK can reduce the&#xD;
      amount of subsequent opioid pain medications required for adequate pain relief in this&#xD;
      population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. The informed consent process will be initiated by investigators in the emergency&#xD;
           department.&#xD;
&#xD;
        2. All potential subjects will be informed that participation in the study could lead to a&#xD;
           positive urine drug test that could remain positive for up to a month after the&#xD;
           conclusion of the study.&#xD;
&#xD;
        3. Female subjects of child bearing age, will have a pregnancy test performed prior to&#xD;
           enrollment; any subjects who are pregnant will be excluded from this project.&#xD;
&#xD;
        4. Each subject will be asked to grade his/her pain severity on a 100mm non-hatched visual&#xD;
           analog scale (VAS) ranging from 0 (no pain) to 100 (worst, maximum pain).&#xD;
&#xD;
        5. Each subject will be asked to fill out a baseline pain questionnaire&#xD;
&#xD;
        6. Each subject will be placed on monitors for continuous pulse oximetry, Heart Rate,&#xD;
           Respiratory Rate, and blood pressure every 5 minutes for the duration of the study of&#xD;
           one hour and longer for any patient who needs continued care. The patients temperature&#xD;
           will be taken prior to the start of the protocol.&#xD;
&#xD;
        7. Each subject will have an intravenous catheter placed.&#xD;
&#xD;
        8. Each subject will be sequentially assigned to one of three treatment groups, based on a&#xD;
           computer-generated randomization schedule, to receive an intravenous infusion of&#xD;
           sub-dissociative Ketamine (0.25mg/kg), sub-dissociative dose Ketamine (0.5mg/kg), or an&#xD;
           equal amount of normal saline.&#xD;
&#xD;
        9. All medications will be prepared by an emergency department pharmacist and all study&#xD;
           medication intravenous bags will be identical in appearance and will be administered by&#xD;
           the emergency department nurse caring for the patient who will be blinded to the study&#xD;
           drug.&#xD;
&#xD;
       10. Each subject will receive lightly tinted sunglasses to wear during the duration of the&#xD;
           study to minimize bias as ketamine can evoke a tell-tale short- lived nystagmus&#xD;
&#xD;
       11. Each subject will receive the study medication over a 20 minute period via an automated&#xD;
           pump. At this point, the subjects will be asked to rate their pain on a VAS and asked if&#xD;
           they need additional pain medication that will consist of intravenous hydromorphone with&#xD;
           the dose and frequency determined by the discretion of the treating physician and&#xD;
           documented on the data collection sheet.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Actual">September 1, 2019</completion_date>
  <primary_completion_date type="Actual">June 22, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Compare the Percentage of Subjects Who Achieved Significant Pain Relief Between the 3 Treatment Groups as Measured by a Visual Analog Pain Scale at 60 Minutes A Decrease of at Least 20 mm on the VAS Will be Considered &quot;Significant&quot; Pain Relief</measure>
    <time_frame>60 minutes</time_frame>
    <description>The primary endpoint was clinically significant pain relief defined a priori as a decrease in the pain VAS of at least 20 mm from baseline, which was arbitrarily chosen as the minimal amount that may be important to this group of patients and was extrapolated from studies of acute pain management in the ED. Using an effect size of 20-mm change in VAS as the marker for a successful outcome and the proportion of successes by group as the analysis point, we performed a power analysis using three groups: 0.5 mg/kg ketamine, 0.25 mg/kg ketamine, and placebo and found that a sample size of 96 subjects would be required to detect a statistically significant difference among groups with a power of 90% (a = 0.05). Expecting a loss of 10% of subjects due to patient withdrawal or incomplete data, 106 subjects were recruited. Only subjects who completed the 60-minute study and had data recorded for each of the time points were included in the analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the Risk for Adverse Events Associated With Sub-dissociative Dose Ketamine</measure>
    <time_frame>1 hour</time_frame>
    <description>Subjects will be continuously assessed for complications secondary to the sub-dissociative ketamine</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo controlled arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>very low dose ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25 mg/kg of sub-dissociative ketamine as an experimental arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low dose ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.50 mg/kg of sub-dissociative ketamine as an experimental arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>sub-dissociative ketamine</description>
    <arm_group_label>low dose ketamine</arm_group_label>
    <arm_group_label>very low dose ketamine</arm_group_label>
    <other_name>ketalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal Saline</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All adult subjects over the age of 18 with chronic pain* presenting to the emergency&#xD;
             department with exacerbation of their chronic pain as their primary complaint&#xD;
&#xD;
          -  Subjects who are willing and able to provide informed consent. *Chronic pain defined&#xD;
             as greater &gt; 3 months of symptoms and an initial VAS pain score &gt; 70&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of overt psychosis, severe hypertension as defined by Systolic Blood Pressure&#xD;
             &gt; 180 mm Hg or Diastolic Blood Pressure &gt;110 mm Hg, unstable angina, Coronary Artery&#xD;
             Disease, Congestive Heart Failure, porphyrias, thyroid disease, seizure disorder,&#xD;
             inability to provide informed consent: dementia, non-English/Spanish speakers,&#xD;
             subjects in custody, suicidal, or clinically intoxicated.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Tanen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Los Angeles Biomedical Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emergency Department, Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 28, 2016</study_first_submitted>
  <study_first_submitted_qc>September 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2016</study_first_posted>
  <results_first_submitted>August 8, 2020</results_first_submitted>
  <results_first_submitted_qc>March 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 15, 2021</results_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</investigator_affiliation>
    <investigator_full_name>David Tanen</investigator_full_name>
    <investigator_title>Professor of Emergency Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT02920528/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>placebo controlled arm&#xD;
Placebo: Normal Saline</description>
        </group>
        <group group_id="P2">
          <title>Very Low Dose Ketamine</title>
          <description>0.25 mg/kg of sub-dissociative ketamine as an experimental arm&#xD;
Ketamine: sub-dissociative ketamine</description>
        </group>
        <group group_id="P3">
          <title>Low Dose Ketamine</title>
          <description>0.50 mg/kg of sub-dissociative ketamine as an experimental arm&#xD;
Ketamine: sub-dissociative ketamine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Incomplete Data</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet inclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>placebo controlled arm&#xD;
Placebo: Normal Saline</description>
        </group>
        <group group_id="B2">
          <title>Very Low Dose Ketamine</title>
          <description>0.25 mg/kg of sub-dissociative ketamine as an experimental arm&#xD;
Ketamine: sub-dissociative ketamine</description>
        </group>
        <group group_id="B3">
          <title>Low Dose Ketamine</title>
          <description>0.50 mg/kg of sub-dissociative ketamine as an experimental arm&#xD;
Ketamine: sub-dissociative ketamine</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="97"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="30"/>
                    <count group_id="B4" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.6" spread="15"/>
                    <measurement group_id="B2" value="44.3" spread="11.2"/>
                    <measurement group_id="B3" value="47.8" spread="11.5"/>
                    <measurement group_id="B4" value="46.5" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="30"/>
                    <count group_id="B4" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="30"/>
                    <count group_id="B4" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Pain as measured by validated Visualized Analog Scale (0 to 100 mm)</title>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="30"/>
                    <count group_id="B4" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91.2" spread="9.4"/>
                    <measurement group_id="B2" value="93.2" spread="8.9"/>
                    <measurement group_id="B3" value="91.4" spread="8.5"/>
                    <measurement group_id="B4" value="91.9" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Compare the Percentage of Subjects Who Achieved Significant Pain Relief Between the 3 Treatment Groups as Measured by a Visual Analog Pain Scale at 60 Minutes A Decrease of at Least 20 mm on the VAS Will be Considered &quot;Significant&quot; Pain Relief</title>
        <description>The primary endpoint was clinically significant pain relief defined a priori as a decrease in the pain VAS of at least 20 mm from baseline, which was arbitrarily chosen as the minimal amount that may be important to this group of patients and was extrapolated from studies of acute pain management in the ED. Using an effect size of 20-mm change in VAS as the marker for a successful outcome and the proportion of successes by group as the analysis point, we performed a power analysis using three groups: 0.5 mg/kg ketamine, 0.25 mg/kg ketamine, and placebo and found that a sample size of 96 subjects would be required to detect a statistically significant difference among groups with a power of 90% (a = 0.05). Expecting a loss of 10% of subjects due to patient withdrawal or incomplete data, 106 subjects were recruited. Only subjects who completed the 60-minute study and had data recorded for each of the time points were included in the analysis.</description>
        <time_frame>60 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo controlled arm&#xD;
Placebo: Normal Saline</description>
          </group>
          <group group_id="O2">
            <title>Very Low Dose Ketamine</title>
            <description>0.25 mg/kg of sub-dissociative ketamine as an experimental arm&#xD;
Ketamine: sub-dissociative ketamine</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Ketamine</title>
            <description>0.50 mg/kg of sub-dissociative ketamine as an experimental arm&#xD;
Ketamine: sub-dissociative ketamine</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Percentage of Subjects Who Achieved Significant Pain Relief Between the 3 Treatment Groups as Measured by a Visual Analog Pain Scale at 60 Minutes A Decrease of at Least 20 mm on the VAS Will be Considered &quot;Significant&quot; Pain Relief</title>
          <description>The primary endpoint was clinically significant pain relief defined a priori as a decrease in the pain VAS of at least 20 mm from baseline, which was arbitrarily chosen as the minimal amount that may be important to this group of patients and was extrapolated from studies of acute pain management in the ED. Using an effect size of 20-mm change in VAS as the marker for a successful outcome and the proportion of successes by group as the analysis point, we performed a power analysis using three groups: 0.5 mg/kg ketamine, 0.25 mg/kg ketamine, and placebo and found that a sample size of 96 subjects would be required to detect a statistically significant difference among groups with a power of 90% (a = 0.05). Expecting a loss of 10% of subjects due to patient withdrawal or incomplete data, 106 subjects were recruited. Only subjects who completed the 60-minute study and had data recorded for each of the time points were included in the analysis.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess the Risk for Adverse Events Associated With Sub-dissociative Dose Ketamine</title>
        <description>Subjects will be continuously assessed for complications secondary to the sub-dissociative ketamine</description>
        <time_frame>1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo controlled arm&#xD;
Placebo: Normal Saline</description>
          </group>
          <group group_id="O2">
            <title>Very Low Dose Ketamine</title>
            <description>0.25 mg/kg of sub-dissociative ketamine as an experimental arm&#xD;
Ketamine: sub-dissociative ketamine</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Ketamine</title>
            <description>0.50 mg/kg of sub-dissociative ketamine as an experimental arm&#xD;
Ketamine: sub-dissociative ketamine</description>
          </group>
        </group_list>
        <measure>
          <title>Assess the Risk for Adverse Events Associated With Sub-dissociative Dose Ketamine</title>
          <description>Subjects will be continuously assessed for complications secondary to the sub-dissociative ketamine</description>
          <units>recorded adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Follow-up Pain Scores Obtained by Telephone at 24 - 48 Hours</title>
        <description>Subjects were contacted by phone 24 - 48 hours after the completion of the study infusion. Subjects were asked to score their pain on 10-point numeric rating scale where 0 represented no pain and 10 represented the worst pain they could be having. Pain score was recorded in increments of 1 from 0 - 10. Results were compared between groups using the Mann-Whitney U-test.</description>
        <time_frame>24 - 48 hours after study drug infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo controlled arm&#xD;
Placebo: Normal Saline</description>
          </group>
          <group group_id="O2">
            <title>Very Low Dose Ketamine</title>
            <description>0.25 mg/kg of sub-dissociative ketamine as an experimental arm&#xD;
Ketamine: sub-dissociative ketamine</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Ketamine</title>
            <description>0.50 mg/kg of sub-dissociative ketamine as an experimental arm&#xD;
Ketamine: sub-dissociative ketamine</description>
          </group>
        </group_list>
        <measure>
          <title>Follow-up Pain Scores Obtained by Telephone at 24 - 48 Hours</title>
          <description>Subjects were contacted by phone 24 - 48 hours after the completion of the study infusion. Subjects were asked to score their pain on 10-point numeric rating scale where 0 represented no pain and 10 represented the worst pain they could be having. Pain score was recorded in increments of 1 from 0 - 10. Results were compared between groups using the Mann-Whitney U-test.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O2" value="5" lower_limit="4" upper_limit="7"/>
                    <measurement group_id="O3" value="6" lower_limit="3" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 48 hours after study enrollment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>placebo controlled arm&#xD;
Placebo: Normal Saline</description>
        </group>
        <group group_id="E2">
          <title>Very Low Dose Ketamine</title>
          <description>0.25 mg/kg of sub-dissociative ketamine as an experimental arm&#xD;
Ketamine: sub-dissociative ketamine</description>
        </group>
        <group group_id="E3">
          <title>Low Dose Ketamine</title>
          <description>0.50 mg/kg of sub-dissociative ketamine as an experimental arm&#xD;
Ketamine: sub-dissociative ketamine</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Patients self-reported feeling nauseated</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Subjects were asked if they felt &quot;dizzy&quot;</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="35"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hallucinations</sub_title>
                <description>Subjects were assessed for hallucinations</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Anxiety and Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Anxiety and Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dysphoria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Tanen</name_or_title>
      <organization>Lundquist Institute</organization>
      <phone>310-222-3624</phone>
      <email>dtanen@emedharbor.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

